• Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 222.58%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.62
▲ +0.0506 (8.89%)

This chart shows the closing price for PHGE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BiomX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHGE

Analyst Price Target is $2.00
▲ +222.58% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BiomX in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 222.58% upside from the last price of $0.62.

This chart shows the closing price for PHGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in BiomX.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.00
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00
12/15/2020Chardan CapitalReiterated RatingBuy$28.00
12/7/2020HC WainwrightReiterated RatingBuy$20.00
12/7/2020HC WainwrightInitiated CoverageBuy$20.00
9/10/2020Chardan CapitalReiterated RatingBuy$28.00
8/11/2020Chardan CapitalReiterated RatingBuy$28.00
3/26/2020Chardan CapitalReiterated RatingBuy$28.00
1/8/2020Cantor FitzgeraldInitiated CoverageOverweight$16.00
(Data available from 12/23/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
BiomX logo
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Read More

Today's Range

Now: $0.62
Low: $0.57
High: $0.63

50 Day Range

MA: N/A

52 Week Range

Now: $0.62
Low: $0.48
High: $8.55

Volume

117,757 shs

Average Volume

107,909 shs

Market Capitalization

$11.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of BiomX?

The following sell-side analysts have issued reports on BiomX in the last year: HC Wainwright.
View the latest analyst ratings for PHGE.

What is the current price target for BiomX?

0 Wall Street analysts have set twelve-month price targets for BiomX in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 222.6%. HC Wainwright has the highest price target set, predicting PHGE will reach $2.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for BiomX in the next year.
View the latest price targets for PHGE.

What is the current consensus analyst rating for BiomX?

BiomX currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PHGE will outperform the market and that investors should add to their positions of BiomX.
View the latest ratings for PHGE.

What other companies compete with BiomX?

How do I contact BiomX's investor relations team?

BiomX's physical mailing address is 22 Einstein Street, Floor 4, Ness Ziona 7414003, Israel. The company's listed phone number is 972-7-2394-2377 and its investor relations email address is [email protected]. The official website for BiomX is www.biomx.com. Learn More about contacing BiomX investor relations.